NRG-LU004 – Cohort 1 has Completed Accrual

01/22/2020

NRG-LU004 has enrolled 6 patients onto the ACRT + MEDI4736 (durvalumab) arm.The next 6 patients will be enrolled to the standard radiation + MEDI4736 (durvalumab) arm.

After a total of 12 patients have been enrolled, the study will temporarily close to accrual in order to monitor the safety of these two regimens.

Please distribute this information to the appropriate personnel at participating affiliate/NCORP component institutions.

Back

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.